The global AIDS related primary CNS lymphoma market size is anticipated to be worth US$ 1,127 Mn in 2022. During the projection period of 2022 to 2032, the market is predicted to grow at a CAGR of 6.65%, reaching a valuation of US$ 2,145.52 Mn by 2032. The following are key factors driving the sales of AIDS-related primary CNS lymphoma:
| Attributes | Details |
|---|---|
| AIDS Related Primary CNS Lymphoma Market (2022) | US$ 1,127 Million |
| AIDS Related Primary CNS Lymphoma Market Forecast Value (2032) | US$ 2,145.52 Million |
| AIDS Related Primary CNS Lymphoma Market CAGR (2022 to 2032) | 6.65% |
Acquired immunodeficiency syndrome (AIDS) is a viral disease of immune system caused by the infection of human immunodeficiency virus (HIV). Primary central nervous system lymphoma (PCNSL) is a primary intracranial tumor occurs mostly in patients suffering from severe immunosuppression specifically AIDS.
The pathogen responsible for primary CNS lymphoma is Epstein-Barr virus. AIDS associated primary CNS lymphoma diffuses large-cell lymphoma of B-cell which usually occurs in brain or spinal cord. Patients suffering from CNS lymphoma complain about lethargy, headache, neurologic symptoms and signs and changes in mental status.
For diagnosing AIDS associated primary CNS lymphoma, Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) is performed. Biopsy diagnosis is also performed to confirm the results as the lesions reported in MRI and CT scan sometimes generate confusion between toxoplasmosis, progressive multifocal leukoencephalopathy (PML) lesions and lympho
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Over the last decade, the AIDS related primary CNS lymphoma market has seen extensive R&D efforts, resulting in the introduction of novel drug-delivery systems. Drug-delivery system advancements are expected to increase the adoption of a novel therapy to treat central nervous system diseases. Due to their fewer side effects, these novel drug-delivery systems outperform traditional methods. The ease of delivery and availability of various dosage forms drive the demand for a novel drug-delivery system.
Government and non-government organizations’ increased awareness of mental health and neurodegenerative diseases is expected to increase treatment rates globally. Organizations such as WHO and others run various awareness campaigns to raise awareness among people who suffer from central nervous system disorders.
Over the forecast period, the presence of strong pipeline products is expected to propel the market for central nervous system therapeutics. The major pharmaceutical companies are concentrating on new therapies to prevent or alleviate the symptoms of neurological disorders. Biogen, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and others have drug candidates in the final stages of development that are expected to be commercialized in the near future.
Large pharmaceutical companies are heavily investing in the development of novel therapies to treat diseases of the central nervous system. Biogen announced a USD 2.72 billion deal with Sangamo Therapeutics in February 2020 to develop gene regulation therapies to treat Alzheimer's disease.
Principal Consultant
Over the last decade, the AIDS related primary CNS lymphoma market has seen extensive R&D efforts, resulting in the introduction of novel drug-delivery systems. Drug-delivery system advancements are expected to increase the adoption of a novel therapy to treat central nervous system diseases. Due to their fewer side effects, these novel drug-delivery systems outperform traditional methods. The ease of delivery and availability of various dosage forms drive the demand for a novel drug-delivery system.
Government and non-government organizations’ increased awareness of mental health and neurodegenerative diseases is expected to increase treatment rates globally. Organizations such as WHO and others run various awareness campaigns to raise awareness among people who suffer from central nervous system disorders.
Over the forecast period, the presence of strong pipeline products is expected to propel the market for central nervous system therapeutics. The major pharmaceutical companies are concentrating on new therapies to prevent or alleviate the symptoms of neurological disorders. Biogen, AbbVie Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and others have drug candidates in the final stages of development that are expected to be commercialized in the near future.
Large pharmaceutical companies are heavily investing in the development of novel therapies to treat diseases of the central nervous system. Biogen announced a USD 2.72 billion deal with Sangamo Therapeutics in February 2020 to develop gene regulation therapies to treat Alzheimer's disease.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market is expected to witness high growth during the forecast period as number of AIDS patients are increasing across the globe. Likewise, increasing awareness initiatives by government authorities would propel the growth of AIDS - related primary CNS lymphoma market.
Also, many pharmaceutical companies are entering into market for developing and manufacturing drugs for preventing and treating AIDS- related primary CNS lymphoma.
Chemotherapy and radiation therapy are administered for treatment of AIDS - related primary CNS lymphoma. AIDS - related primary CNS lymphoma. Various drugs have been utilized during chemotherapy sessions include methotrexate, thiotepa and procarbazine.
For increasing treatment efficiency, rituximab is combined with methotrexate. Temozolomide is also used with those patients who demonstrate fair response to the treatment. The major therapy used for treating AIDS associated primary CNS lymphoma is Highly Active Antiretroviral Therapy (HAART).
Moreover, several clinical trials are being conducted in order to develop and commercialize more precise and exclusive treatments for the condition.
Depending on geographic regions, global AIDS - related primary CNS lymphoma market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. North America and Eastern Europe markets are currently at the maturity stage for clinical research and methods for treating AIDS associated primary CNS lymphoma due to their position to use expensive drugs and treatment.
However, Asia-Pacific market looks attractive for AIDS associated primary CNS lymphoma treatment owing to increasing awareness among the people about the treatment availability. Considering the treatment types, HAART occupies the major market share among the other available treatments.
The institutes which are majorly involved in clinical research for AIDS associated primary CNS lymphoma treatments are the National Cancer Institute, National Institute of Allergy and Infectious diseases, AIDS Malignancy Clinical Trials Consortium, European Organization for Research and Treatment of Cancer and Eastern Cooperative Oncology Group.
Some of the key players in global AIDS - related primary CNS lymphoma market are Fresenius SE & Co. KGaA, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Celon Laboratories Limited among several others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.
The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
AIDS - related primary CNS lymphoma market is classified on the basis of drug type, distribution channel and geography.
Explore Healthcare Insights
View Reports
AIDS Related Primary CNS Lymphoma Market
